{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro+Esophageal+Junction+Cancer&page=15", "query": { "condition": "Gastro Esophageal Junction Cancer", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 406, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro+Esophageal+Junction+Cancer&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro+Esophageal+Junction+Cancer&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T12:01:45.678Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06532006", "title": "A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal-junction Cancer", "Monoclonal Antibody", "Gastric Cancer", "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "HLX22", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2024-11-22", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 29, "location_summary": "Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06532006" }, { "nct_id": "NCT00004235", "title": "Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2000-01", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004235" }, { "nct_id": "NCT05709574", "title": "Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Tadalafil 20 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2023-04-20", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05709574" }, { "nct_id": "NCT04681248", "title": "Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Esophageal Neoplasm", "Adenocarcinoma of the Gastroesophageal Junction", "GastroEsophageal Cancer", "Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Endometrial Cancer", "Uterine Cancer", "Ovarian Cancer", "Carcinosarcoma", "Gastric Cancer" ], "interventions": [ { "name": "DKN-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681248" }, { "nct_id": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "GAd-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "GAd-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "GAd20-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nouscom SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-10-21", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041310" }, { "nct_id": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Esophageal Carcinoma", "Advanced Unresectable Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Esophageal Cancer", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastric Carcinoma", "Unresectable Esophageal Cancer", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "AgenT-797", "type": "BIOLOGICAL" }, { "name": "Botensilimab", "type": "BIOLOGICAL" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-02-01", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06251973" }, { "nct_id": "NCT04460937", "title": "Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Distal Esophagus Adenocarcinoma", "Gastric Cardia Adenocarcinoma", "Metastatic Esophageal Adenocarcinoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Leptomeninges", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Esophageal Adenocarcinoma", "Unresectable Esophageal Carcinoma", "Unresectable Esophageal Squamous Cell Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-04-09", "completion_date": "2026-12-18", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 7, "location_summary": "Duarte, California • Chicago, Illinois • Lexington, Kentucky + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460937" }, { "nct_id": "NCT03196232", "title": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Unresectable Esophageal Carcinoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Albert Fisher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-09-13", "completion_date": "2018-05-29", "has_results": true, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03196232" }, { "nct_id": "NCT04520867", "title": "STRENGTH Expansion", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "STRENGTH", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-08-06", "completion_date": "2021-11-16", "has_results": false, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04520867" }, { "nct_id": "NCT06657144", "title": "A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "CHS-114", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "5 Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2025-04-01", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-23T12:01:45.678Z", "location_count": 20, "location_summary": "Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06657144" } ] }